Literature DB >> 22138208

Interplay of estrogen receptors and GPR30 for the regulation of early membrane initiated transcriptional effects: A pharmacological approach.

George Notas1, Marilena Kampa, Vassiliki Pelekanou, Elias Castanas.   

Abstract

Estrogens exert their effect through ERα and ERβ intracellular transcription factors and rapid, usually membrane-initiated receptors, influencing cytosolic signaling and transcription. The nature of extranuclear estrogen elements has not been elucidated so far; classical or alternatively transcribed ER isoforms (ERα36, ERα46) anchored to the plasma membrane and GPR30 (GPER1) have been reported to exert early estrogen actions. Here, we used E2-BSA, an impermeable estradiol analog for a transcriptome analysis in four GREP1 positive breast cancer cell lines with different estrogen receptor profiles (T47D, MCF-7, MDA-MB-231 and SKBR3) in order to evaluate GPER1 transcriptional effects. Early effects of E2-BSA were assayed after 3h of incubation, in the absence/presence of ICI182,780 (ER-inhibitor) or G15 (GREP1-specific inhibitor). E2-BSA specifically modified 277-549 transcripts in the different cell lines. Two different clusters of transcripts could be identified: (1) the majority of transcripts were inhibited by both ICI182,780 and G15, suggesting an interaction of E2-BSA with a common ER-related element, or a direct ER-GPER1 interaction; (2) a small number of G15-only modified transcripts, in two cell lines (T47D and SKBR3 cells), indicative of specific GPER1-related effects. The latter transcripts were significantly related to pathways including FOXA2/FOXA3 transcription factor networks, RNA-Polymerases Transcription Regulation and lipid metabolism, while ICI/G15 inhibited transcripts affected pathways related to apoptosis, erythropoietin signaling, metabolic effects through the citric acid cycle, IL-4 and IL-5 mediated events and homologous DNA recombination. Finally, we review the current literature of GPER1 actions, in view of our results of ER-dependent and independent GPER1-modified pathways.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22138208     DOI: 10.1016/j.steroids.2011.11.005

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  16 in total

1.  Dehydroepiandrosterone Activation of G-protein-coupled Estrogen Receptor Rapidly Stimulates MicroRNA-21 Transcription in Human Hepatocellular Carcinoma Cells.

Authors:  Yun Teng; Brandie N Radde; Lacey M Litchfield; Margarita M Ivanova; Russell A Prough; Barbara J Clark; Mark A Doll; David W Hein; Carolyn M Klinge
Journal:  J Biol Chem       Date:  2015-05-11       Impact factor: 5.157

2.  Tamoxifen induces a pluripotency signature in breast cancer cells and human tumors.

Authors:  George Notas; Vassiliki Pelekanou; Marilena Kampa; Konstantinos Alexakis; Stelios Sfakianakis; Aggelos Laliotis; John Askoxilakis; Eleftheria Tsentelierou; Maria Tzardi; Andreas Tsapis; Elias Castanas
Journal:  Mol Oncol       Date:  2015-06-05       Impact factor: 6.603

Review 3.  Crosstalk between nuclear and G protein-coupled estrogen receptors.

Authors:  Shannon N Romano; Daniel A Gorelick
Journal:  Gen Comp Endocrinol       Date:  2017-04-25       Impact factor: 2.822

Review 4.  Rewiring of the Endocrine Network in Triple-Negative Breast Cancer.

Authors:  Kaixuan Li; Dongjiang Zong; Jianrong Sun; Danxiang Chen; Minkai Ma; Liqun Jia
Journal:  Front Oncol       Date:  2022-06-30       Impact factor: 5.738

5.  GPER1/GPR30 activation improves neuronal survival following global cerebral ischemia induced by cardiac arrest in mice.

Authors:  Y Kosaka; N Quillinan; Ct Bond; Rj Traystman; Pd Hurn; Ps Herson
Journal:  Transl Stroke Res       Date:  2012-09-12       Impact factor: 6.829

6.  Whole transcriptome analysis of the ERα synthetic fragment P295-T311 (ERα17p) identifies specific ERα-isoform (ERα, ERα36)-dependent and -independent actions in breast cancer cells.

Authors:  George Notas; Marilena Kampa; Vassiliki Pelekanou; Maria Troullinaki; Yves Jacquot; Guy Leclercq; Elias Castanas
Journal:  Mol Oncol       Date:  2013-02-20       Impact factor: 6.603

Review 7.  Erythropoietin and cancer: the unintended consequences of anemia correction.

Authors:  Nataša Debeljak; Peter Solár; Arthur J Sytkowski
Journal:  Front Immunol       Date:  2014-11-11       Impact factor: 7.561

8.  GPR30 decreases with vascular aging and promotes vascular smooth muscle cells maintaining differentiated phenotype and suppressing migration via activation of ERK1/2.

Authors:  Fang Huang; Jianguo Yin; Keyu Li; Ying Li; Heng Qi; Li Fang; Cong Yuan; Weiwei Liu; Min Wang; Xiangping Li
Journal:  Onco Targets Ther       Date:  2016-06-07       Impact factor: 4.147

9.  N-3 poly-unsaturated fatty acids shift estrogen signaling to inhibit human breast cancer cell growth.

Authors:  Wenqing Cao; ZhiFan Ma; Mark M Rasenick; ShuYan Yeh; JiangZhou Yu
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

10.  Contrasting effect of recombinant human erythropoietin on breast cancer cell response to cisplatin induced cytotoxicity.

Authors:  Nina Trost; Peter Juvan; Gregor Sersa; Natasa Debeljak
Journal:  Radiol Oncol       Date:  2012-06-19       Impact factor: 2.991

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.